{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:23:06Z","timestamp":1791397386913,"version":"4.3.3"},"reference-count":43,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,1,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Patients with angioimmunoblastic T-cell lymphoma (AITL) have poor prognoses with current conventional chemotherapy. The aim of this study was to evaluate the effect of high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) on patients with AITL. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> We report a retrospective, multicenter study of 146 patients with AITL who received ASCT. The source of the stem cells was peripheral blood in 143 patients. The conditioning regimen varied, and 74% of the patients received carmustine and 1,3-bis(2-chloroethyl)-1-nitrosourea; etoposide; ara-C; and melphalan chemotherapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> After a median follow-up of 31 months (range, 3 to 174 months), 95 patients (65%) remained alive, and 51 patients (35%) died. Forty-two patients died as a result of disease progression, and nine died as a result of regimen-related toxicity. The cumulative incidence of nonrelapse mortality was 5% and 7% at 12 and 24 months, respectively. The actuarial overall survival (OS) was 67% at 24 months and 59% at 48 months. The cumulative incidence of relapse was estimated at 40% and 51% at 24 and 48 months, respectively. Disease status at transplantation was the major factor that impacted outcome. Patients who received a transplant during first complete remission (CR) had significantly superior progression-free survival and OS. The estimated PFS rates for patients who received their transplants in CR were 70% and 56% at 24 and 48 months, respectively; 42% and 30% for patients with chemotherapy-sensitive disease at those time points, respectively; and 23% at both time points for patients with chemotherapy-refractory disease. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> This study shows that HDT and ASCT offers the possibility of long-term disease-free survival to patients with AITL. Early transplantation is necessary to achieve optimal results. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2008.12.6219","type":"journal-article","created":{"date-parts":[[2007,12,11]],"date-time":"2007-12-11T01:53:58Z","timestamp":1197338038000},"page":"218-224","source":"Crossref","is-referenced-by-count":44,"title":["High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome\u2014Lymphoma Working Party of the European Group for Blood and Marrow Transplantation"],"prefix":"10.1200","volume":"26","author":[{"given":"Charalampia","family":"Kyriakou","sequence":"first","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Canals","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Goldstone","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Caballero","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Metzner","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Jochem","family":"Kolb","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Kienast","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reimer","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Finke","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Oberg","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hunter","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Theorin","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[{"name":"From the University College London; European Bone Marrow Transplantation Group, London; and Leicester Royal Infirmary, Leicester, United Kingdom; Hospital Cl\u00ednico Servicio de Hematolog\u00eda, Salamanca; and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University Hospital, Dept. of Hematology; and University Hospital, Department of Medicine, Uppsala, Sweden; University of Freiburg, Department of Medicine -Hematology, Oncology, Freiburg; Medical Klinik, Wurzburg; University of M\u00fcnster, Department of..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf033"},{"key":"R3","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, et al: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 92:76,1998-82,"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-4-575"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909058412"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1007\/BF00255768"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1159\/000206997"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Siegert W, Agthe A, Griesser H, et al: Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM\/IMVP-16 regimen: A multicenter study. Kiel Lymphoma Study Group Ann Intern Med 117:364,1992-370,","DOI":"10.7326\/0003-4819-117-5-364"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200136"},{"key":"R10","unstructured":"Gerlando Q, Barbera V, Ammatuna E, et al: Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined methotrexate and prednisone. Haematologica 85:880,2000-881,"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050244"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01139.x"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Bourgeois E, Auxenfants E, Jouffrey C, et al: [Efficacy of fludarabine in the treatment of angioimmunoblastic lymphoma (AIL)]. Ann Med Interne (Paris) 151:230,2000-231,","DOI":"10.1016\/S0248-8663(99)80361-0"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Feremans WW, Khodadadi E: Alpha-interferon therapy in refractory angioimmunoblastic lymphadenopathy. Eur J Haematol 39:91,1987,","DOI":"10.1111\/j.1600-0609.1987.tb00176.x"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Hast R, Gustafsson B: Improved response to chemotherapy after interferon alpha-2b in angioimmunoblastic lymphadenopathy (AILD). Eur J Haematol 46:51,1991-52,","DOI":"10.1111\/j.1600-0609.1991.tb00515.x"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909058489"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb04544.x"},{"key":"R18","unstructured":"Siegert W, Nerl C, Meuthen I, et al: Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy: Results in 12 patients. Leukemia 5:892,1991-895,"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008275208592"},{"key":"R20","unstructured":"Takemori N, Kodaira J, Sato T, et al: Successful treatment of IBL-like T-cell lymphoma with cyclosporin A: Two case reports with special reference to serum cytokine levels. Hum Cell 13:35,2000-42,"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920515)69:10<2567::AID-CNCR2820691029>3.0.CO;2-M"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1080\/10428190210190"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403710"},{"key":"R24","unstructured":"Schetelig J, Fetscher S, Reichle A, et al: Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 88:1272,2003-1278,"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703260"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703271"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-002-0450-y"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290016926"},{"key":"R31","unstructured":"Schmitz N, Prange E, Haferlach T, et al: High-dose chemotherapy and autologous bone marrow transplantation in relapsing angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). Bone Marrow Transplant 8:503,1991-506,"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702867"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00134-X"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.17.3766"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Kyriakou C, Attygalle A, Linch D, and Babis. Angioimmunoblastic T-Cell Lymphoma: A Large Series Outcome Analysis. Blood 106: Issue 11, 2005. (abstr 2810)","DOI":"10.1182\/blood.V106.11.2810.2810"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.3025"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.075"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.050"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02743.x"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600961058"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06457.x"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3389"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Weidmann E, Hess G, Krause SW. Combination chemoimmunotherapy using alemtuzumab, fludarabine, cyclophosphamide and doxorubicin (Campath-FCD) is an effective first-line regimen in peripheral T-cell lymphoma. Blood 104: 2004 (abstr 2640)","DOI":"10.1182\/blood.V104.11.2640.2640"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.12.6219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:14:36Z","timestamp":1653509676000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.12.6219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,10]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,1,10]]}},"alternative-id":["10.1200\/JCO.2008.12.6219"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.12.6219","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,10]]}}}